Patents by Inventor Zhizhen Barbara Zheng

Zhizhen Barbara Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11618753
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 4, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Publication number: 20200347071
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Application
    Filed: January 24, 2019
    Publication date: November 5, 2020
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Patent number: 10407410
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 10, 2019
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Michael A. Walker, Tao Wang, Zhiwei Yin, Zhongxing Zhang, Zhizhen Barbara Zheng
  • Publication number: 20190127351
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Manoj PATEL, Michael A. WALKER, Tao WANG, Zhiwei YIN, Zhongxing ZHANG, Zhizhen Barbara ZHENG
  • Patent number: 10125148
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: November 13, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Timothy P. Connolly, Stanley D'Andrea, John F. Kadow, David R. Langley, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Michael A. Walker, Zhongyu Wang, Zhizhen Barbara Zheng
  • Publication number: 20170008909
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 19, 2014
    Publication date: January 12, 2017
    Inventors: Timothy P. CONNOLLY, Stanley D'ANDREA, John F. KADOW, David R. LANGLEY, B. Narasimhulu NAIDU, Manoj PATEL, Kevin PEESE, Michael A. WALKER, Zhongyu WANG, Zhizhen Barbara ZHENG
  • Patent number: 9540393
    Abstract: The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: January 10, 2017
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng
  • Patent number: 9273067
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Michael A. Walker, Margaret E. Sorenson, Manoj Patel, Zhizhen Barbara Zheng, John F. Kadow, Bin Zheng, Martin D. Eastgate, Ke Chen, Francisco Gonzalez-Bobes
  • Publication number: 20160039844
    Abstract: The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 11, 2016
    Inventors: B. Narasimhulu NAIDU, MANOJ PATEL, STANLEY D'ANDREA, ZHIZHEN BARBARA ZHENG
  • Publication number: 20150232481
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 20, 2015
    Inventors: B. Narasimhulu Naidu, Michael A. Walker, Margaret E. Sorenson, Manoj Patel, Zhizhen Barbara Zheng, John F. Kadow, Bin Zheng, Martin D. Eastgate, Ke Chen, Francisco Gonzalez-Bobes
  • Patent number: 9006235
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: April 14, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea, David R. Langley, B. Narasimhulu Naidu
  • Patent number: 8906929
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 9, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Patent number: 8716275
    Abstract: The present invention provides (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1 -methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl) carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea
  • Publication number: 20140051692
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 20, 2014
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Publication number: 20130237499
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 12, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea, David R. Langley, B. Narasimhulu Naidu
  • Patent number: 8343477
    Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R3, R?3, R4, R6, R?, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Paul Michael Scola
  • Patent number: 7772183
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 10, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: David J. Carini, Barry L. Johnson, Zhizhen Barbara Zheng, Stanley D'Andrea, Paul Michael Scola
  • Patent number: 7741281
    Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R?, R3, R3?, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: June 22, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Jeffrey Allen Campbell, Fiona McPhee, Andrew Charles Good, Paul Michael Scola
  • Patent number: 7173004
    Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fiona McPhee, Jeffrey Allen Campbell, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, Paul Michael Scola, Kenneth M. Boy